Brain Immune Protein GPNMB Linked to Spread of Parkinson's Disease Pathology
Similar Articles
Research Identifies Protein Target That Improves Memory in Alzheimer's Mouse Model
Elevated Immune Cell Ratio Linked to Higher Dementia Risk in Large Study
Engineered Nanoparticles Show Promise in Restoring Brain Waste Removal in Alzheimer's Mouse Model
Scientists Develop Drug Method to Boost Natural Killer Cells Against Multiple Cancers
Researchers Identify Brain Cell Process That Removes Alzheimer's Plaques in Mice
Researchers have identified a brain immune protein, GPNMB, that appears to assist the spread of Parkinson's disease-related damage between neurons. The findings, based on analysis of over 1,600 brain samples and preclinical experiments, suggest this protein is a specific target for the disease. This discovery could lead to new therapies aimed at slowing the progression of Parkinson's, which currently has no disease-modifying treatments.
Facts First
- Researchers identified glycoprotein nonmetastatic melanoma B (GPNMB) as a protein involved in Parkinson's disease progression.
- Brain immune cells called microglia produce GPNMB when nearby neurons are damaged or dying.
- Higher GPNMB levels correlate with more extensive Parkinson's pathology in human brain tissue analysis.
- Antibodies targeting GPNMB prevented pathology spread in preclinical cell culture experiments.
- Current Parkinson's treatments reduce symptoms but do not slow the underlying disease progression.
What Happened
Researchers at the Perelman School of Medicine at the University of Pennsylvania have identified a brain immune protein, GPNMB, that may play a role in the progression of Parkinson's disease (PD). The protein appears to assist the spread of Parkinson's-related damage from one brain cell to another. The findings, published in the journal Neuron, build on 2022 research that first identified GPNMB as a molecule involved in the spread of alpha-synuclein, the protein that forms abnormal clumps in Parkinson's disease. The team found that microglia, the brain's immune cells, are a major source of GPNMB in Parkinson's disease, producing larger amounts when nearby neurons become damaged or begin dying.
Why this Matters to You
While this is a laboratory discovery, it represents a potential step toward treatments that could slow or stop Parkinson's disease progression, which affects more than one million Americans. Current treatments only manage symptoms. If therapies targeting GPNMB prove successful in future human trials, they could help preserve the quality of life for those diagnosed with Parkinson's and their families. The research also suggests GPNMB is specific to Parkinson's pathology, which could lead to more precise diagnostics.
What's Next
The research team has already developed antibodies that successfully prevented alpha-synuclein pathology from spreading between cells in laboratory experiments. This finding could lead to the development of new drugs or immunotherapies designed to block GPNMB's function. Further research will be needed to test these approaches in animal models and, eventually, in human clinical trials to determine if they can safely and effectively slow Parkinson's disease progression.